The injectable GLP-1 RAs liraglutide 3 mg once daily and semaglutide 2.4 mg once weekly have both gained a licence for weight loss, alongside lifestyle management, in obese/overweight people without T2D (SmPC, 2023b
So now, really, the challenge before all of us is to move much more expeditiously from evidence generation to implementation.
2,3 The guidance outlines requirements for manufacturers that aim to conduct randomized trials specifically designed to evaluate CV safety of new medications prior to submission of New Drug Applications (NDAs)
The clinic is cash-pay only, and HSA or FSA cards are the workaround at checkout
Intermittent fasting and eating disorder symptoms: A systematic review
It is essential not to discontinue Ozempic without medical guidance, as abrupt cessation may lead to deterioration in glycaemic control